FDA.reportPublic FDA data

Yuflyma Pediatric Crohn's Disease Starter Package (3 count)

RxCUI
2668492
RxNorm name
Yuflyma Pediatric Crohn's Disease Starter Package (3 count)
Display name
Yuflyma Pediatric Crohn's Disease Starter Package (3 count)
Full name
Yuflyma Pediatric Crohn's Disease Starter Package (3 count)
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:58

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761219Yuflymaadalimumab-aaty351(k) InterchangeableRx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
YuflymaADALIMUMAB-AATYCELLTRION USA, Inc.526d626f-8c9f-496c-b838-00a73bb363832026-07-15Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2668492

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
526d626f-8c9f-496c-b838-00a73bb36383{3 (0.8 ML adalimumab-aaty 100 MG/ML Prefilled Syringe [Yuflyma]) } Pack [Yuflyma Pediatric Crohn's Disease Starter Package (3 count)] [BPCK] · Yuflyma Pediatric Crohn's Disease Starter Package (3 count) [PSN] · Yuflyma Pediatric Crohn's Disease Starter Package (3 count) [SY]313These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe20251028